Lambert, JRA;
Howe, SJ;
Rahim, AA;
Burke, DG;
Heales, SJR;
(2019)
Inhibition of Mitochondrial Complex I Impairs Release of α-Galactosidase by Jurkat Cells.
International Journal of Molecular Sciences
, 20
(18)
, Article 4349. 10.3390/ijms20184349.
Preview |
Text
Heales ijms-20-04349-v2.pdf - Published Version Download (1MB) | Preview |
Abstract
Fabry disease (FD) is caused by mutations in the GLA gene that encodes lysosomal α-galactosidase-A (α-gal-A). A number of pathogenic mechanisms have been proposed and these include loss of mitochondrial respiratory chain activity. For FD, gene therapy is beginning to be applied as a treatment. In view of the loss of mitochondrial function reported in FD, we have considered here the impact of loss of mitochondrial respiratory chain activity on the ability of a GLA lentiviral vector to increase cellular α-gal-A activity and participate in cross correction. Jurkat cells were used in this study and were exposed to increasing viral copies. Intracellular and extracellular enzyme activities were then determined; this in the presence or absence of the mitochondrial complex I inhibitor, rotenone. The ability of cells to take up released enzyme was also evaluated. Increasing transgene copies was associated with increasing intracellular α-gal-A activity but this was associated with an increase in Km. Release of enzyme and cellular uptake was also demonstrated. However, in the presence of rotenone, enzyme release was inhibited by 37%. Excessive enzyme generation may result in a protein with inferior kinetic properties and a background of compromised mitochondrial function may impair the cross correction process.
Archive Staff Only
 |
View Item |
